11/17
08:06 am
ipsc
Century Therapeutics (NASDAQ:IPSC) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $7.00.
Low
Report
Century Therapeutics (NASDAQ:IPSC) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $7.00.
11/17
07:28 am
ipsc
Rating for IPSC
Low
Report
Rating for IPSC
11/17
06:23 am
ipsc
Century Therapeutics downgraded to Market Perform from Outperform at Leerink
Low
Report
Century Therapeutics downgraded to Market Perform from Outperform at Leerink